首页
400-620-6333
durvalumab
| 别名 | anti-B7H1 monoclonal antibody, MEDI4736, MEDI-4736, Imfinzi® |
|---|---|
| Compound Class | Antibody |
| 变动原因 |
Durvalumab is a monoclonal antibody directed against programmed death-1 ligand-1 (PD-L1, aka CD274), an important immunopharmacological drug discovery target in immuno-oncology. Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. A patent search suggests that the development and use of durvalumab may be covered by patent WO2011066389 |
| Related Product | Durvalumab (anti-PD-L1) |
Summary
| 是否批准为药物？ | (FDA (2017), EMA (2018)) |
|---|---|
| IUPAC Name | 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide |
| 别名 | anti-B7H1 monoclonal antibody, MEDI4736, MEDI-4736, Imfinzi® |
数据库链接
| IMGT/mAb-DB | 528 |
|---|---|
| Wikipedia | Durvalumab |
生物活性
| 生物活性评价 | The affinity value in the table below is that reported in patent WO2011066389. |
|---|
临床资料
| Summary of Clinical Use | Durvalumab (MEDI-4736) was 'fast tracked' to Phase 3 clinical trial, then receiving full FDA approval in May 2017 for the treatment of advanced/metastatic bladder cancer (urothelial carcinoma) in patients who have already received platinum-containing chemotherapy. In February 2018 FDA approval was expanded to include treatment of some stage III non-small cell lung cancer (NSCLC) patients. It is hoped that durvalumab may show clinical efficacy against other cancers. Click here to link to ClinicalTrials.gov's list of Phase 2 and 3 studies evaluating MEDI-4736 in additional cancer types. |
|---|---|
| 作用机制与药效学效应 | Anti-PD-L1 antibodies interfere with PD-L1 signalling, which results in the activation of tumour-detecting/infiltrating T cells. The drug’s mechanism of action enables the immune cells to detect and destroy tumour cells. |
参考文献
| 1. Queva C, Morrow M, Hammond S, Alimzhanov M, Babcock J, Foltz I, Kang JS, Sekirov L, Boyle M, Chodorge M. (2011) Targeted binding agents against b7-h1.. Drugs, 71 (13): (1755-70). [PMID:21902297] |
| 2. Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ, Ryu SE, Shin W, Heo YS. (2017) Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab.. Sci Rep, 7 (1): (5532). [PMID:28717238] |
危险品化学品经营许可证（带存储）